USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Shanghai Henlius Biotech, Inc.

USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Shanghai ranks #42,932 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.

#42,932
of 49,997 US assignees by volume
Top 24%
by Innovation Score (45.0/100)
17.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R42932 · Foreign Corporation #42,932 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 6 grants
  • LOWER-Q #42,932/49,997
  • PHOTO-FINISH Shandong Zhonghai…
  • CPC-NARROW A61P · 5 areas
  • INNOV-PAR 45.0/100
  • CLAIMS-RICH 17.3 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Shandong Zhonghai Pharmaceutical Co. Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Shanghai

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Shanghai's Innovation Score is 45.0/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Shanghai's grants concentrate

Shanghai Henlius Biotech, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2021. By volume, Shanghai sits between Shandong Zhonghai Pharmaceutical Co. Ltd and Shanghai Jiaotong University School OF Medicine.

Shanghai's three-year grant acceleration

Shanghai Henlius Biotech, Inc. shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Shanghai's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Shanghai holds 6 patents at rank #42,815, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Shanghai

By rank, the assignees closest to #42,815 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Shanghai's primary technology class.

Shanghai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2021202220232025 1
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Shanghai Henlius Biotech, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 16.7%
2022 2 33.3%
2023 2 33.3%
2025partial year 1 16.7%

Where it ranks

Overall rank by patents

#42,932

of 49,997 tracked assignees

Innovation Score

45.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Shanghai Henlius Biotech, Inc.'s patent record in context - here's where to go next.

  • Shanghai Henlius Biotech, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #42,932 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Shanghai Henlius Biotech, Inc. against Shandong Zhonghai Pharmaceutical Co. Ltd, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 45.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.